← Leaderboards
John Danias
Mount Sinai School Of Medicine Of Nyu
$8,763,854
Attributed
$9,931,803
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,931,803 · 9
VA$0 · 1
By mechanism
R01$8,155,765 · 5
K08$613,074 · 1
R03$493,905 · 1
R56$369,059 · 1
R41$300,000 · 1
I01$0 · 1
Top collaborators
- Oscar A Candia3 shared
- Yiqin Du1 shared
- Yubing Xie1 shared
Others in their field
Top investigators on “Glaucoma”
- Rohit Varma · University Of Southern California$58,233,961
- Janey L Wiggs · Massachusetts Eye And Ear Infirmary$36,083,461
- Cecilia Sungmin Lee · University Of Washington$32,086,169
- David Huang · Cleveland Clinic Lerner Col/Med-Cwru$27,740,623
- Linda M Zangwill · University Of California San Diego$23,025,291
- Robert N Weinreb · University Of California, San Diego$21,784,031
Research focus
GlaucomaAffectOptic Nerve DisorderPathway InteractionsAnimalsCellsResponseGenesMouse ModelPlayTissuesRetinaPathologyPhysiologic Intraocular PressureMolecularFunctional DisorderExtracellular MatrixGene ExpressionBaseOpen-Angle GlaucomaBlindnessPathogenesisAxonPrevent
Grant awards (33)
Elucidating the molecular changes of the outflow pathway extracellular matrix that regulate outflow facility in steroid-induced ocular hypertension and open angle glaucoma$661,635
R01 · FY2025 · EY · contact PI
Tissue plasminogen activator for the treatment of glaucoma$0
I01 · FY2025 · VA · contact PI
Tissue plasminogen activator for the treatment of glaucoma$0
I01 · FY2024 · VA · contact PI
Tissue plasminogen activator for the treatment of glaucoma$0
I01 · FY2023 · VA · contact PI
Gene therapy to treat glaucoma by reducing intraocular pressure$300,000
R41 · FY2021 · EY · contact PI
CTGF Function in Retinal Vessel Development and Pathology$403,750
R01 · FY2020 · EY · contact PI
tPA mechanisms in outflow facility regulation in glaucoma$347,456
R01 · FY2019 · EY · contact PI
tPA mechanisms in outflow facility regulation in glaucoma$347,456
R01 · FY2018 · EY · contact PI
tPA mechanisms in outflow facility regulation in glaucoma$347,456
R01 · FY2017 · EY · contact PI
tPA mechanisms in outflow facility regulation in glaucoma$347,456
R01 · FY2016 · EY · contact PI
tPA mechanisms in outflow facility regulation in glaucoma$360,214
R01 · FY2015 · EY · contact PI
Molecular mechanisms in steroid-induced glaucoma.$487,258
R01 · FY2012 · EY
Complement activation in glaucoma$241,287
R01 · FY2012 · EY · contact PI
Complement activation in glaucoma$53,800
R01 · FY2012 · EY · contact PI
Complement activation in glaucoma$605,705
R01 · FY2011 · EY · contact PI
Molecular mechanisms in steroid-induced glaucoma.$472,591
R01 · FY2011 · EY
Complement activation in glaucoma$65,942
R01 · FY2011 · EY · contact PI
Complement activation in glaucoma$634,045
R01 · FY2010 · EY · contact PI
Molecular mechanisms in steroid-induced glaucoma.$493,869
R01 · FY2010 · EY
Complement activation in glaucoma$627,673
R01 · FY2009 · EY · contact PI
Complement activation in glaucoma$251,548
R56 · FY2008 · EY · contact PI
Complement activation in glaucoma$117,511
R56 · FY2008 · EY · contact PI
Retinal gene expression changes in glaucoma$411,475
R01 · FY2007 · EY · contact PI
Retinal gene expression changes in glaucoma$413,792
R01 · FY2006 · EY · contact PI
Retinal gene expression changes in glaucoma$423,750
R01 · FY2005 · EY
Retinal gene expression changes in glaucoma$409,155
R01 · FY2004 · EY
Non-invasive assessment of murine intraocular pressure$169,500
R03 · FY2003 · EY
ANTISENSE INHIBITION OF RETINAL GLUTAMATE METABOLISM$161,823
K08 · FY2003 · EY
Non-invasive assessment of murine intraocular pressure$169,500
R03 · FY2002 · EY
ANTISENSE INHIBITION OF RETINAL GLUTAMATE METABOLISM$146,547
K08 · FY2002 · EY
ANTISENSE INHIBITION OF RETINAL GLUTAMATE METABOLISM$166,568
K08 · FY2001 · EY
Non-invasive assessment of murine intraocular pressure$154,905
R03 · FY2001 · EY
ANTISENSE INHIBITION OF RETINAL GLUTAMATE METABOLISM$138,136
K08 · FY2000 · EY